Nektar Therapeutics
(NASDAQ:NKTR)
$1.62
-0.02[-1.22%]
At close: May 9
$1.62
0[0.00%]
After Hours: 7:36PM EDT
Q1 2024 earnings were released today after the market close
Today's conference call ended over 9 hours ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Nektar Therapeutics Stock (NASDAQ:NKTR), Quotes and News Summary

Nektar Therapeutics Stock (NASDAQ: NKTR) stock price, news, charts, stock research, profile.

Open$1.640
Close$1.600
Volume / Avg.970.000K / 2.566M
Day Range1.600 - 1.690
52 Wk Range0.413 - 1.790
Market Cap$297.471M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
61
Short Interest
2.17%
Days to Cover1

Recent News

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Avi Kapoor
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
Lisa Levin
Why Is Nektar Therapeutics Stock Surging Today?
Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b studies of its atopic dermatitis drug, 
Vandana Singh
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Nov 23
0
0
0
0
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
2.2
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
NKTR
AVIR

FAQ

Q

How do I buy Nektar Therapeutics (NKTR) stock?

A

You can purchase shares of Nektar Therapeutics (NASDAQ: NKTR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Nektar Therapeutics's (NKTR) competitors?

A

Other companies in Nektar Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), Zevra Therapeutics (NASDAQ:ZVRA), Xeris Biopharma Holdings (NASDAQ:XERS) and Terns Pharma (NASDAQ:TERN).

Q

What is the target price for Nektar Therapeutics (NKTR) stock?

A

The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by Jefferies on Wednesday, March 6, 2024. The analyst firm set a price target for 1.00 expecting NKTR to fall to within 12 months (a possible -38.27% downside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Nektar Therapeutics (NKTR)?

A

The stock price for Nektar Therapeutics (NASDAQ: NKTR) is $1.62 last updated May 9, 2024 at 7:36 PM EDT.

Q

Does Nektar Therapeutics (NKTR) pay a dividend?

A

There are no upcoming dividends for Nektar Therapeutics.

Q

When is Nektar Therapeutics (NASDAQ:NKTR) reporting earnings?

A

Nektar Therapeutics’s Q2 earnings are confirmed for Tuesday, August 6, 2024.

Q

Is Nektar Therapeutics (NKTR) going to split?

A

There is no upcoming split for Nektar Therapeutics.

Q

What sector and industry does Nektar Therapeutics (NKTR) operate in?

A

Nektar Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch